EGFR and metastatic colorectal cancer: In almost 60% metastatic colorectal cancer (mCRC) patients, K-RAS and N-RAS are mutated and mutations are considered a predictor of poor response to anti-EGFR monoclonal antibodies (mABs), such as cetuximab or panitumumab, while patients with wild-type RAS benefit from EGFR targeted treatment [13].